ALZINOVA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.37 SEK | +13.41% |
|
+17.50% | -54.86% |
| Apr. 25 | Sweden’s Alzinova Says CEO to Step Down by July-end | MT |
| Apr. 25 | Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024 | CI |
| Sales 2023 | 270K 25.15K | Sales 2024 * | 51.5M 4.8M | Capitalization | 61.01M 5.68M |
|---|---|---|---|---|---|
| Net income 2023 | -16M -1.49M | Net income 2024 * | 6M 559K | EV / Sales 2023 | 419 x |
| Net cash position 2023 | 22.03M 2.05M | Net cash position 2024 * | 69.1M 6.44M | EV / Sales 2024 * | -0.16 x |
| P/E ratio 2023 |
-7.4
x | P/E ratio 2024 * |
13.7
x | Employees | 4 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 63.38% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +13.41% | ||
| 1 week | +17.50% | ||
| Current month | +22.32% | ||
| 1 month | -26.82% | ||
| 3 months | -36.28% | ||
| 6 months | -46.38% | ||
| Current year | -54.86% |
1 week
1.10
1.78
1 month
1.011.83
Current year
1.013.20
1 year
1.013.92
3 years
0.9812.00
5 years
0.9819.80
10 years
0.9844.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 19-12-15 | |
Anders Sandberg
FOU | Founder | 52 | 11-08-16 |
Kirsten Harting
CTO | Chief Tech/Sci/R&D Officer | - | 23-08-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anders Waas
BRD | Director/Board Member | 67 | 17-12-31 |
| Director/Board Member | 68 | 19-12-31 | |
Julian Aleksov
CHM | Chairman | 59 | 22-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 1.37 | +13.41% | 707,465 |
| 24-05-22 | 1.208 | +1.00% | 115,394 |
| 24-05-21 | 1.196 | +1.36% | 164,250 |
| 24-05-20 | 1.18 | +3.51% | 55,142 |
| 24-05-17 | 1.14 | -0.87% | 109,606 |
Delayed Quote Nasdaq Stockholm, May 23, 2024 at 11:24 am EDT
More quotes
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâs disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -54.86% | 5.01M | |
| +64.92% | 62.59B | |
| -1.85% | 41.18B | |
| +44.76% | 40.29B | |
| -8.93% | 27.9B | |
| +13.05% | 26.21B | |
| -21.96% | 19.09B | |
| +4.21% | 13.08B | |
| +25.74% | 12.26B | |
| +27.42% | 12.05B |
- Stock Market
- Equities
- ALZ Stock
